Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus

Lara-Barea, Almudena; Sánchez-Lechuga, Begoña; Campos‐Caro, Antonio; Córdoba-Doña, Juan Antonio; Varga-Martínez, Raquel de la; Arroba, Ana I.; Bugatto, Fernando; Diosdado, Manuel Aguilar; López-Tinoco, Cristina

doi:10.3390/jcm11061514

Cited by 8 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with a positive screening test with a 1-h blood glucose > 140 mg/dL (7.7 mmol/L) underwent a confirmatory 3-h, 100 g—OGTT. GDM is diagnosed with two abnormally high values of the following thresholds: fasting glucose level ≥ 105 mg/dL (5.8 mmol/L); 1-h, ≥190 mg/dL (10.5 mmol/L); 2-h, ≥165 mg/dL (9.1 mmol/L); 3-h, ≥145 mg/dL (8.0 mmol/L) [ 103 , 104 ].…”

Section: Europementioning

confidence: 99%

Evolution of Gestational Diabetes Mellitus across Continents in 21st Century

Dłuski

Ruszała

Rudziński

et al. 2022

IJERPH

View full text Add to dashboard Cite

Over the last few decades, several definitions of gestational diabetes mellitus (GDM) have been described. There is currently not enough research to show which way is the best to diagnose GDM. Opinions differ in terms of the optimal screening and diagnostic measures, in part due to the differences in the population risks, the cost-effectiveness considerations, and the lack of an evidence base to support large national screening programs. The basic method for identifying the disease is the measurement of glucose plasma levels which may be determined when fasting, two hours after a meal, or simply at any random time. The currently increasing incidence of diabetes in the whole population, the altering demographics and the presence of lifestyle changes still require better methods of screening for hyperglycemia, especially during pregnancy. The main aim of this review is to focus on the prevalence and modifications to the screening criteria for GDM across all continents in the 21st century. We would like to show the differences in the above issues and correlate them with the geographical situation. Looking at the history of diabetes, we are sure that more than one evolution in GDM diagnosis will occur, due to the development of medicine, appearance of modern technologies, and the dynamic continuation of research.

show abstract

Section: Europementioning

confidence: 99%

Evolution of Gestational Diabetes Mellitus across Continents in 21st Century

Dłuski

Ruszała

Rudziński

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Several authors have studied the association between adiponectin and preeclampsia and found conflicting results. Most studies report an increase of adiponectin in the third trimester of gestation in patients with preeclampsia compared to control ( Pérez-Pérez et al, 2020 ; Pheiffer et al, 2021 ; Lara-Barea et al, 2022 ), while others found the Other adipokines such as resistin, visfatin and vaspin in gestational diabetes and preeclampsia have been described but their physiological role has yet to be established and work has been more descriptive regarding these other adipokines ( Miehle et al, 2012 ). In pregnant women plasma levels of resistin are elevated compared to non-pregnant women, however in gestational diabetes there are inconsistent data in the literature with some studies demonstrating elevation of resistin while others found decreased levels.…”

Section: Discussionmentioning

confidence: 99%

Association of LEPTIN and other inflammatory markers with preeclampsia: A systematic review

et al. 2022

View full text Add to dashboard Cite

Background: Preeclampsia is a serious pregnancy complication that affects 5%–10% of the obstetric population.Objective: To study inflammatory markers associated with preeclampsia.Search Strategy: Searches of articles on the topic published over a 10-year period (2009–2019) were performed in three databases (PubMed, Cochrane, and Embase) using the keywords preeclampsia and inflammatory markers. The PubMed search using 10 years and humans as filters retrieved 124 articles. Using an advanced search strategy, 0 articles were identified in Embase and 10 articles in Cochrane. After screening and eligibility assessment, 13 articles were included in the systematic review and meta-analysis. Meta-analysis and quality assessment of the studies were performed using the Review Manager 5.3 program.Results: For meta-analysis, women with preeclampsia were compared to control women, i.e., pregnancies without arterial hypertension. Leptin levels were significantly higher (p < 0.0002) in women with preeclampsia compared to controls. Total cholesterol was also significantly elevated in women with preeclampsia (p < 0.0001). There was no significant difference in HDL between groups, but women with preeclampsia had significantly increased LDL (p < 0.01). The same was observed for triglycerides, which were significantly increased in women with preeclampsia (p < 0.04) compared to controls. Analysis of TNF-alpha, an important inflammatory marker, showed higher levels in women with preeclampsia (p < 0.03) compared to controls. The same was observed for another important inflammatory marker, interleukin 6, which was significantly increased in women with preeclampsia (p < 0.0002). There was a significant increase of C-reactive protein in women with preeclampsia (p < 0.003) compared to controls.Conclusion: Women with preeclampsia have increased levels of inflammatory markers compared to control women.

show abstract

“…Before compared to after 34 weeks of gestation, both assays performed better. Lara-Barea et al (12) reported that higher levels of the (sFlt-1/PIGF) ratio were associated with a 2.7fold increased risk of developing HDP in women.…”

Section: Discussionmentioning

confidence: 99%

Angiogenic Biomarkers (sFlt / PLGF): An Approach for Clinical Integration of Pre-eclampsia

Elmazny

Abo-Hashem²,

El-Hussiny³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: One of the most important pregnancy problems is pre-eclampsia (PE). PE is caused by changes in the circulating levels of angiogenic agents. Endothelial dysfunction is caused by elevated levels of antiangiogenic factors like soluble fms-like tyrosine kinase-1(sFlt-1) and decreased levels of angiogenic factors like placental growth factor (PlGF). Objective: This study's objective is to assess the significance of alternation of angiogenic balance as a preeclamptic marker and their association to PE severity. Patients and Methods: One hundred pregnant women in third trimester participated in this case-control study, with 40 having mild PE, 40 having severe PE, and 20 healthy pregnant ladies as control. It was done in Clinical Pathology and Obstetrics and Gynecology Departments of Mansoura University Hospitals during a period from "November 2020 to April 2022". Clinical and laboratory tests on all individuals were performed, including CBC, LDH, sFlt-1 in the serum, PLGF, liver function tests, renal function tests. Results: In comparison to the control group, greater levels of sFlt-1 and sFlt-1/PLGF and lower levels of PLGF were present in all cases of mild and severe PE (p0.001 for each). Additionally, severe cases demonstrated significant high levels of sFlt-1 and sFlt-1/PLGF and significant low levels of PLGF with superior AUCs when compared to moderate instances (AUC=0.999). Conclusion: sFlt-1, PLGF and sFlt-1/PLGF ratio may have a role in the prediction of severity of PE, and thus diagnosis of PE, thus may be used in management of PE.

show abstract

Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus

Cited by 8 publications

References 54 publications

Evolution of Gestational Diabetes Mellitus across Continents in 21st Century

Evolution of Gestational Diabetes Mellitus across Continents in 21st Century

Association of LEPTIN and other inflammatory markers with preeclampsia: A systematic review

Angiogenic Biomarkers (sFlt / PLGF): An Approach for Clinical Integration of Pre-eclampsia

Contact Info

Product

Resources

About